Jingjuan Wu1,#, Yinli Wang2,#, Wei Wei3,*
1Chengbu Minkang Mental Hospital, Changsha 410000, Hunan, China.
2Zhanjiang South China Psychiatric Hospital, Zhanjiang 524000, Guangdong, China.
3921 Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Changsha 410000, Hunan, China.
#Both authors contributed equally to this manuscript.
*Corresponding author: Wei Wei
Abstract
Objective: To explore the efficacy and safety of low-dose perphenazine in the treatment of psychotic symptoms in elderly patients with dementia. Methods: A total of 60 elderly patients with dementia and psychotic symptoms admitted to the hospital from January 2024 to December 2024 were selected and divided into two groups of 30 patients each using the random number table method. The control group (30 cases) received conventional treatment, while the observation group (30 cases) received low-dose perphenazine in addition to conventional treatment. The efficacy and safety were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05). The scores of all indicators of the Senile Clinical Assessment Geriatric Scale (SCAG) changed in both groups before and after treatment, and the improvement in the observation group was more significant after treatment, with a statistically significant difference (P<0.05). The incidence of adverse reactions in the observation group was significantly low-er (P<0.05). Conclusion: Low-dose perphenazine has significant efficacy and good safety in the treatment of psychotic symptoms of senile dementia. It can effectively improve the total effective rate of treatment, significantly improve the mental state and living ability of patients, and has fewer adverse reactions.
References
[1] Alzheimer's Association. 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020;16(3):391-460.
[2] Jia J, Chen S. Neurology. 8th ed. Beijing: People's Medical Publishing House; 2018:229-36.
[3] Fong CY, Hon S. Use of an amyloid β-directed antibody in Alzheimer's disease. MIMS Doctor. 2024(Sept).
[4] Defourny P, Van Sambeek N, Hester VDB, et al. Dynamics of recovery in psychosis, stigmatization, and microaggressions in mental healthcare: a qualitative study of service users' narratives. BMC Psychiatry. 2024;24(1):1-13. doi:10.1186/s12888-024-06262-5
[5] Sicotte R, D'Andrea G, Dumais A, et al. Aggressive behaviors in first-episode psychosis: distinction between the premorbid phase and the onset of psychosis. Schizophr Res. 2024;271:283-91. doi:10.1016/j.schres.2024.07.033
[6] Sheetal S, Mathew R. Cognitive stimulation therapy in dementia - are we sufficiently stimulated? Ann Indian Acad Neurol. 2024;27(1):9-10.
[7] Fan J, Geng D. Psychiatry. 2nd ed. Nanjing: Southeast University Press; 2009.
[8] Messina A, Barone R, Sturiale L, et al. CSF N-glycomics using high-throughput UPLC-ESI techniques in Alzheimer's disease. Methods Mol Biol. 2024;2785:37-48.
[9] Ikha Y, Arroyantri PB. Tardive dyskinesia as a side effect of combination administration of haloperidol and risperidone in schizophrenic patient with pasung: a case report. Int J Neuropsychopharmacol. 2025(Suppl 1):Suppl 1.
[10] Defourny P, Van Sambeek N, Hester VDB, et al. Dynamics of recovery in psychosis, stigmatization, and microaggressions in mental healthcare: a qualitative study of service users' narratives. BMC Psychiatry. 2024;24(1):1-13.
[11] Mcintyre RS, Llorca PM, Aronin LC, et al. Effect of cariprazine on anhedonia in patients with bipolar I depression: post hoc analysis of three randomized placebo-controlled clinical trials. Adv Ther. 2025;42(1).
How to cite this paper
Efficacy and Safety of Low-dose Perphenazine in the Treatment of Psychotic Symptoms of Senile Dementia
How to cite this paper: Jingjuan Wu, Yinli Wang, Wei Wei. (2025) Efficacy and Safety of Low-dose Perphenazine in the Treatment of Psychotic Symptoms of Senile Dementia. International Journal of Clinical and Experimental Medicine Research, 9(3), 299-304.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.05.008